156 related articles for article (PubMed ID: 38482580)
1. Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy: a multicenter prospective trial.
Zhang N; Jiang H; Dai H; Huang S; Zhao Q; Zhang N; Liu W; Dong Z; Gao Y; Dong X; Hu Y; Hou F; Rui H; Liu Q; Liu B
Ren Fail; 2024 Dec; 46(1):2320834. PubMed ID: 38482580
[TBL] [Abstract][Full Text] [Related]
2. Activation of the IL-6/STAT3 pathway contributes to the pathogenesis of membranous nephropathy and is a target for Mahuang Fuzi and Shenzhuo Decoction (MFSD) to repair podocyte damage.
Zhao Q; Dai H; Jiang H; Zhang N; Hou F; Zheng Y; Gao Y; Liu W; Feng Z; Hu Y; Tang X; Rui H; Liu B
Biomed Pharmacother; 2024 May; 174():116583. PubMed ID: 38626520
[TBL] [Abstract][Full Text] [Related]
3. Effect of Mahuang Fuzi and Shenzhuo Decoction on Idiopathic Membranous Nephropathy: A Multicenter, Nonrandomized, Single-Arm Clinical Trial.
Dong Z; Dai H; Gao Y; Jiang H; Liu M; Liu F; Liu W; Feng Z; Zhang X; Ren A; Li X; Rui H; Tian X; Li G; Liu B
Front Pharmacol; 2021; 12():724744. PubMed ID: 34733157
[No Abstract] [Full Text] [Related]
4. The Ameliorative Effect of Mahuang Fuzi and Shenzhuo Decoction on Membranous Nephropathy of Rodent Model is Associated With Autophagy and Wnt/β-Catenin Pathway.
Gao Y; Dai H; Zhang N; Jiang H; Zhang Z; Feng Z; Dong Z; Liu W; Liu F; Dong X; Zhao Q; Zhou X; Du J; Zhang N; Rui H; Liu B
Front Pharmacol; 2022; 13():820130. PubMed ID: 35529432
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
[TBL] [Abstract][Full Text] [Related]
6. Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time.
Zhang N; Dai H; Dong X; Liu W; Jiang H; Zhao Q; Gao Y; Feng Z; Dong Z; Hu Y; Huang G; Rui H; Liu B
Front Immunol; 2022; 13():926368. PubMed ID: 35983038
[TBL] [Abstract][Full Text] [Related]
7. Alleviation by Mahuang Fuzi and Shenzhuo Decoction in High Glucose-Induced Podocyte Injury by Inhibiting the Activation of Wnt/
Dai H; Liu F; Qiu X; Liu W; Dong Z; Jia Y; Feng Z; Liu Z; Zhao Q; Gao Y; Zhang Z; Gao C; Sun S; Tian X; Liu B
Evid Based Complement Alternat Med; 2020; 2020():7809427. PubMed ID: 32963573
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
9. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE
Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
Liang Q; Li H; Xie X; Qu F; Li X; Chen J
Ren Fail; 2017 Nov; 39(1):512-518. PubMed ID: 28562168
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
[TBL] [Abstract][Full Text] [Related]
12. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.
Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC
Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis.
Zhang J; Bian L; Ma FZ; Jia Y; Lin P
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):8021-8029. PubMed ID: 30536351
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial.
Chen Y; Deng Y; Ni Z; Chen N; Chen X; Shi W; Zhan Y; Yuan F; Deng W; Zhong Y
Am J Kidney Dis; 2013 Dec; 62(6):1068-76. PubMed ID: 23810688
[TBL] [Abstract][Full Text] [Related]
16. Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study.
Jiang Z; Cai M; Dong B; Yan Y; Wang Y; Li X; Shao C; Zuo L
BMC Nephrol; 2021 Apr; 22(1):148. PubMed ID: 33888083
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Long-Term Corticosteroid Monotherapy in 26 Cases of Nephrotic Syndrome with Biopsy-Proven Membranous Nephropathy Induced by Seronegative Hepatitis B Virus-Associated Glomerulonephritis.
Zhang Y; Chen S; Yang D; Liu J; Zhang X; Yang X; Han H; Yang D
Nephron; 2021; 145(2):113-122. PubMed ID: 33561853
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
[TBL] [Abstract][Full Text] [Related]
19. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Schieppati A; Perna A; Zamora J; Giuliano GA; Braun N; Remuzzi G
Cochrane Database Syst Rev; 2004 Oct; (4):CD004293. PubMed ID: 15495098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
